Cognoptix Elects Its President And CEO, Paul D. Hartung, As Chairman Of The Board, And Welcomes New Director, Dr. Christine De Los Reyes, Alopexx Enterprises
ACTON, Mass.--(BUSINESS WIRE)--Cognoptix, an emerging medical device company that is developing the SAPPHIRE II eye test designed to identify Alzheimer’s Disease (AD) patients via a beta-amyloid (A-beta) signature in their eyes, announced today that it has elected its President and CEO, Paul D. Hartung, as Chairman of the Board. The company also announced that it has elected a new director: Christine de los Reyes, PharmD, Vice President, Business Development and Strategic Planning, Alopexx Enterprises LLC.
On Sept. 30, 2014, Cognoptix announced that it closed the first tranche of a Series D round of financing totaling over $15 million. The round was co-led by new investor Alopexx and existing investor Inventages, with participation from original investor, Launchpad Venture Group.
Help employers find you! Check out all the jobs and post your resume.
On Sept. 30, 2014, Cognoptix announced that it closed the first tranche of a Series D round of financing totaling over $15 million. The round was co-led by new investor Alopexx and existing investor Inventages, with participation from original investor, Launchpad Venture Group.
Help employers find you! Check out all the jobs and post your resume.